Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, between 18 and 65 years of age (inclusive, at time of informed consent)~* Has definite MS according to the McDonald criteria~* Has relapsing-remitting disease with 1 or more relapses within 12 months prior to Study Day 1~* Must have been clinically stable and not has a relapse within 28 days prior to Study Day 1~* Has MRI consistent with MS at the pre-study evaluation according to the Fazekas criteria~* Has a EDSS score from 0 to 5.5, inclusive~* Weighed between 40-120 kilogram (kg), inclusive~* If female, she must:~  1. be post-menopausal or surgically sterilized; or~ 2. uses a hormonal contraceptive, intra uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study; and~ 3. be neither pregnant nor breast-feeding~* If male, he must be willing to use contraception to avoid pregnancies~* Be willing and able to comply with study procedures for the duration of the study~* Voluntarily provides written informed consent, and for United states of America (USA) sites only, a subject authorization under Health Insurance Portability and Accountability Act (HIPAA)~Exclusion Criteria:~* Has secondary progressive MS (SPMS) or primary progressive MS (PPMS)~* Prior use of disease modifying drugs (DMDs) within the last 3 months, or 2 or more prior treatment failures with DMDs on the basis of efficacy~* Has significant leukopenia (white blood cell count less than 0.5 times the lower limit of normal of the central laboratory) within 28 days prior to Study Day 1~* Has received cladribine, mitoxantrone, total lymphoid irradiation, myelosuppressive therapy, campath-1h, cyclophosphamide, azathioprine, methotrexate or natalizumab~* Has received oral or systemic corticosteroids or adrenocorticotropic hormone within 28 days prior to Study Day 1~* Has compromised immune function or infection~* Has received oral or systemic corticosteroids or adrenocorticotropic hormone within 28 days prior to Study Day 1~* Has received cytokine-based therapy, intravenous immunoglobulin therapy, or plasmapheresis within 3 months prior to Study Day 1~* Has platelet and absolute neutrophil counts below the lower limit of normal range within 28 days prior to Study Day 1~* Has prior or current history of malignancy~* Has a history of persistent anemia, leukopenia, neutropenia, or thrombocytopenia after immunosuppressive therapy~* Has systemic disease that, in the opinion of the Investigator, might interfere with subject safety, compliance or evaluation of the condition under Study (for example, insulin-dependent diabetes, Lyme disease, clinically significant cardiac, hepatic, or renal disease, Human Immunodeficiency Virus, or Human T-Cell Lymphotrophic Virus Type-1)~* Has a psychiatric disorder that, in the opinion of the Investigator, was unstable or would preclude safe participation in the study~* Has allergy or hypersensitivity to gadolinium, to cladribine or any of its excipients~* Has used any investigational drug or experimental procedure within 6 months prior to Study Day 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cladribine 5.25 mg/kg (Type: EXPERIMENTAL): None
- Cladribine 3.5 mg/kg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).